Median Effective Dose (ED50) of Esketamine Combined With Alfentanil for Children to Inhibit Body Movement During Laser Treatment for Facial Lesion

XJA-20240224

There is limited research on the combined use of esketamine and alfentanil for anesthesia during facial laser treatment in pediatric patients, and the effective dosage of esketamine for inhibiting body movement remains unclear. We explore the effective dose of esketamine combined with alfentanil for the inhibition of body movement during facial laser treatment in pediatric patients.

2024-03-27

2025-03-27

2025-04-27

Not yet recruiting

40

Inclusion Criteria: * age between 3 years and 12 years old * patients scheduled for laser treatment of facial lesion Exclusion Criteria: * patients with airway infection during the last 1 month * patients with cardiac or pulmonary disorder * patients with hepatic or renal disfunction * patients with neurologic or psychiatric disorder

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SEQUENTIAL', 'interventionModelDescription': 'The Biased coin method is used', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'Esketamine will be prepared by an investigator who is not involved in anesthesia and outcome assessment. For all participants, esketamine will be diluted to the same volume.'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}

2024-03-05